Abstract: The present invention relates to 3?3?-cyclic dinucleotides modified with a 3?-phosphonoalkyl bond and derivatives thereof, that can modulate the activity of the STING adaptor protein.

Abstract: The present disclosure relates to 2?3? cyclic phosphonate dinucleotides of general formula (J), their pharmaceutically acceptable salts, their pharmaceutical composition and combinations of said substances and other medicaments or pharmaceuticals. The disclosure also relates to the use of said compounds for the treatment or prevention of diseases or conditions modifiable by STING protein modulation, such as cancer or viral, allergic and inflammatory diseases. In addition, these substances can be used as adjuvants in vaccines.

Abstract: The present disclosure relates to 2?3?-cyclic dinucleotides modified with a 2?- or 3?-phosphonoalkyl bond and derivatives thereof, that can modulate the activity of the STING adaptor protein.

Abstract: Provided herein are the 3?3? cyclic phosphonate dinucleotides of general formula J, their pharmaceutically acceptable salts, a pharmaceutical composition containing them and combinations of said substances and other medicaments or pharmaceuticals. The disclosure also relates to the use of said compounds for the treatment or prevention of diseases or conditions modifiable by STING protein modulation, such as cancer or viral, allergic and inflammatory diseases. In addition, these substances can be used as adjuvants in vaccines.

Abstract: The present invention relates to 3?3?-cyclic dinucleotides modified with a 3?-phosphonoalkyl bond and derivatives thereof, that can modulate the activity of the STING adaptor protein.

Abstract: The present disclosure relates to 2?3?-cyclic dinucleotides modified with a 2?- or 3?-phosphonoalkyl bond and derivatives thereof, that can modulate the activity of the STING adaptor protein.

Abstract: The present invention relates to 2?2?-cyclic dinucleotides modified with a 2?-phosphonoalkyl bond and derivatives thereof, that can modulate the activity of the STING adaptor protein.

Abstract: The present disclosure relates to 2?3? cyclic phosphonate dinucleotides of general formula (J), their pharmaceutically acceptable salts, their pharmaceutical composition and combinations of said substances and other medicaments or pharmaceuticals. The disclosure also relates to the use of said compounds for the treatment or prevention of diseases or conditions modifiable by STING protein modulation, such as cancer or viral, allergic and inflammatory diseases. In addition, these substances can be used as adjuvants in vaccines.

Abstract: Provided herein are the 3?3? cyclic phosphonate dinucleotides of general formula J, their pharmaceutically acceptable salts, a pharmaceutical composition containing them and combinations of said substances and other medicaments or pharmaceuticals. The disclosure also relates to the use of said compounds for the treatment or prevention of diseases or conditions modifiable by STING protein modulation, such as cancer or viral, allergic and inflammatory diseases. In addition, these substances can be used as adjuvants in vaccines.

Abstract: Provided herein are 2?2? cyclic phosphonate dinucleotides of formula (J), their pharmaceutically acceptable salts, hydrates or solvates, a pharmaceutical composition containing them and combinations of said substances and other medicaments or pharmaceuticals. The disclosure also relates to the use of said compounds for the treatment or prevention of diseases or conditions modifiable by STING protein modulation, such as cancer or viral, allergic and inflammatory diseases. In addition, the dinucleotides can be used as adjuvants in vaccines.

Abstract: This invention relates to new nucleotide analogues and solves the technical problem of their use as biologically active compounds. The subject of this invention are N-(2-phosphonylmethoxyethyl) and N-(3-hydroxy-2-phosphonylmethoxypropyl) derivatives of pyrimidine and purine bases, easily accessible from heterocyolic bases and their N-(2-hydroxyethyl) or N-(2,3-dihydroxypropyl) derivatives. Some of the compounds, according to this invention, exhibit a marked antiviral activity or can be converted into such active compounds by chemical transformations.

Abstract: This invention relates to new nucleotide analogues and solves the technical problem of their use as biologically active compounds. The subject of this invention are N-(2-phosphonylmethoxyethyl) and N-(3-hydroxy-2-phosphonylmethoxypropyl) derivatives of pyrimidine and purine bases, easily accessible from heterocyclic bases and their N-(2-hydroxyethyl) or N-(2,3-dihydroxypropyl) derivatives. Some of the compounds, according to this invention, exhibit a marked antiviral activity or can be converted into such active compounds by chemical transformations.

Abstract: This invention relates to new nucleotide analogues and solves the technical problem of their use as biologically active compounds. The subject of this invention are N-(2-phosphonylmethoxyethyl) and N-(3-hydroxy-2-phosphonylmethoxypropyl) derivatives of pyrimidine and purine bases, easily accessible from heterocyclic bases andd their N-(2-hydroxyethyl) or N-(2,3-dihydroxypropyl) derivatives. Some of the compounds, according to this invention, exhibit a marked antiviral activity or can be converted into such active compounds by chemical transformations.

Abstract: The invention relates to 9-(phosphonylmethoxyalkyl)adenines of the general formula I ##STR1## wherein R.sup.1 is a hydrogen atom, and alkyl group containing one to three carbon atoms, or a hydroxymethyl group, R.sup.2 is a methylene, ethylene, propylene, ethylidene, methoxyethylene, benzyloxyethylene, tetrahydropyran-2-yloxyethylene, (1-ethoxyethoxy)ethylene or 1,2-O-isopropylidene-1,2-dihydroxypropylene group the method of their preparation and utilization.Compounds of the general formula I exhibit biological effects (e.g. antiviral) or can be converted into compounds with such effects.

Abstract: The (S) and (RS) forms of certain phosphonylmethoxyalkyl adenines and their salts have an antiviral effect against several DNA viruses and can be used for the treatment of virus diseases in human and veterinary medicine.

Abstract: This invention relates to isomeric O-phosphonylmethyl derivatives of the formula I ##STR1## wherein R.sup.5 designates an adenin-9-yl moiety, R.sup.4 are alternately a hydrogen atom and a --CH.sub.2 P(O)(OH).sub.2 group, and the configuration at the carbon atom in the position 2 is S, R or RS.The compounds according to the invention are biologically active as inhibitors of metabolic processes and in organism they are stable towards enzymes, cleaving phosphomonoester bonds.The said compounds exhibit also chemosterilizing action on insects.